版本:
中国

BRIEF-TESARO announces U.S. FDA approval of zejula for women with recurrent ovarian cancer

March 27 TESARO Inc -

* TESARO announces U.S. FDA approval of zejula™ (niraparib) for women with recurrent ovarian cancer

* TESARO anticipates launching zejula in United States in late April

* Marketing authorisation application for niraparib is under review by European Medicines Agency Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐